Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Enzyme Inhib Med Chem. 2009 Oct;24(5):1169-78. doi: 10.1080/14756360802696802.

Anticancer and immunomodulatory activities of novel 1,8-naphthyridine derivatives.

Author information

  • 1Chemical Research, Dabur Research Foundation, Sahibabad, Ghaziabad, 201 010 UP, India. kumarv@dabur.com

Abstract

A number of 1,8-naphthyridine derivatives (22-62) have been synthesized and screened for their in vitro cytotoxicity against eight tumors and two non-tumor cell lines. Halogen substituted 1,8-naphthyridine-3-caboxamide derivatives showed potent activity with compound 47 having IC(50) of 0.41 and 0.77 microM on MIAPaCa and K-562 cancer cell lines, respectively while, compound 36 had IC(50) of 1.19 microM on PA-1 cancer cell line. However, one of the unsubstituted 1,8-naphthyridine-C-3'-heteroaryl derivative 29 showed potent cytotoxicity with IC(50) of 0.41 and 1.4 microM on PA-1 and SW620 cancer cell lines, respectively. These compounds were also evaluated for anti-inflammatory activity as suggested by downregulation of proinflammaotory cytokines.

PMID:
19555167
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk